Sulfacetamid
(преусмерено са I-Sulfacet)
Sulfacetamid je organsko jedinjenje, koje sadrži 8 atoma ugljenika i ima molekulsku masu od 214,242 Da.[1][2][3][4][5]
![]() | |
![]() | |
Klinički podaci | |
---|---|
Prodajno ime | Albamine, Albucid, Alesten, Bleph-10 |
Drugs.com | Monografija |
Način primene | Oftalmički |
Farmakokinetički podaci | |
Poluvreme eliminacije | 7-12,8 h |
Identifikatori | |
CAS broj | 144-80-9 ![]() |
ATC kod | S01AB04 (WHO) |
PubChem | CID 5320 |
DrugBank | DB00634 ![]() |
ChemSpider | 5129 ![]() |
ChEBI | CHEBI:63845 ![]() |
ChEMBL | CHEMBL455 ![]() |
Hemijski podaci | |
Formula | C8H10N2O3S |
Molarna masa | 214,242 |
| |
| |
Fizički podaci | |
Tačka topljenja | 183 °C (361 °F) |
Osobine
уредиOsobina | Vrednost |
---|---|
Broj akceptora vodonika | 4 |
Broj donora vodonika | 2 |
Broj rotacionih veza | 2 |
Particioni koeficijent[6] (ALogP) | -0,2 |
Rastvorljivost[7] (logS, log(mol/L)) | -2,0 |
Polarna površina[8] (PSA, Å2) | 97,6 |
Reference
уреди- ^ Hull CA, Johnson SM: A double-blind comparative study of sodium sulfacetamide lotion 10% versus selenium sulfide lotion 2.5% in the treatment of pityriasis (tinea) versicolor. Cutis. 2004 Jun;73(6):425-9. PMID 15224788
- ^ Del Rosso JQ: Evaluating the role of topical therapies in the management of rosacea: focus on combination sodium sulfacetamide and sulfur formulations. Cutis. 2004 Jan;73(1 Suppl):29-33. PMID 14959943
- ^ Roth HW, Leimbeck R, Sonnenschein B, Anger CB, Weber S: [The effective antibacterial spectrum of sulfacetamide] Klin Monatsbl Augenheilkd. 1992 Mar;200(3):182-6. PMID 1578876
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
- ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.
- ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
- ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e.
Literatura
уреди- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze
уреди
Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |